List of Excipients in Branded Drug APLENZIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	APLENZIN	bupropion hydrobromide	0187-5810	CARNAUBA WAX	2026-06-27
Bausch Health US LLC	APLENZIN	bupropion hydrobromide	0187-5810	CROSPOVIDONE	2026-06-27
Bausch Health US LLC	APLENZIN	bupropion hydrobromide	0187-5810	DIBUTYL SEBACATE	2026-06-27
Bausch Health US LLC	APLENZIN	bupropion hydrobromide	0187-5810	ETHYLCELLULOSE	2026-06-27

Aplenzin Excipient Strategy and Commercial Opportunities

Last updated: September 26, 2026

APLENZIN is a once-daily extended-release bupropion hydrobromide tablet for major depressive disorder and prevention of seasonal major depressive episodes. Its commercial value is tied to controlled release, dose flexibility, salt-specific formulation work, and a limited but defensible opportunity for generic or reformulated products. The key excipient platform is a hydrophobic extended-release matrix built around ethylcellulose and glyceryl behenate, supported by povidone, hydroxypropyl cellulose, colloidal silicon dioxide, and magnesium stearate.[1]

What is APLENZIN and how is it formulated?

APLENZIN contains bupropion hydrobromide in three extended-release strengths:

APLENZIN strength	Approximate bupropion base equivalent	Administration
174 mg	150 mg	Once daily
348 mg	300 mg	Once daily
522 mg	450 mg	Once daily

The product is an extended-release tablet. The 522 mg strength is the maximum recommended daily dose for adults receiving treatment for major depressive disorder. Tablets must be swallowed whole and must not be crushed, divided, or chewed because those actions can affect release characteristics and increase exposure risk.[1]

APLENZIN uses bupropion hydrobromide rather than the hydrochloride salt used in Wellbutrin and Wellbutrin XL. The distinction affects molecular weight, dose labeling, tablet composition, and regulatory comparability. A product containing the hydrochloride salt is not automatically substitutable for APLENZIN.

What excipients are used in APLENZIN tablets?

The FDA prescribing information identifies the following inactive ingredients:

Excipient	Likely formulation function
Ethylcellulose	Hydrophobic release-controlling polymer and matrix former
Glyceryl behenate	Lipid matrix former and release retardant
Hydroxypropyl cellulose	Binder, granulation aid, and matrix-supporting polymer
Povidone	Binder and granulation aid
Colloidal silicon dioxide	Glidant and processing aid
Magnesium stearate	Lubricant

The FDA label identifies composition but does not assign a functional role to each excipient. The functional assignments above are based on standard pharmaceutical use and the requirements of an extended-release matrix system.[1-3]

Why ethylcellulose matters

Ethylcellulose is the principal release-control opportunity in the formulation. It is water-insoluble and can slow liquid penetration and drug diffusion. In a matrix tablet, its performance depends on polymer grade, particle size, viscosity, concentration, granulation conditions, compression force, and tablet porosity.

For a generic or reformulated APLENZIN product, small changes in ethylcellulose characteristics can alter:

• Initial drug release
• Release rate over 24 hours
• Food-effect behavior
• Dose proportionality
• Tablet hardness and friability
• Sensitivity to manufacturing scale-up

This gives the formulation a meaningful quality-by-design dimension. The excipient itself is commercially available, but the combination of grade, loading, processing, and dissolution target can create practical development barriers.

Why glyceryl behenate matters

Glyceryl behenate is a lipid excipient that can reduce wetting and slow drug diffusion. It may also improve tablet structure and contribute to the extended-release profile. The interaction between glyceryl behenate and ethylcellulose is commercially important because the two materials can provide release control through different mechanisms.

A competitor that replaces glyceryl behenate with a different lipid, hydrophilic polymer, or multiparticulate system could avoid a narrow formulation claim. It would still need to reproduce the reference product’s in vitro and in vivo release behavior.

Why the binder system matters

Povidone and hydroxypropyl cellulose support granule formation and mechanical integrity. Their levels can affect:

• Granule density
• Tablet tensile strength
• Drug dissolution
• Compression performance
• Manufacturing yield
• Stability under humidity and temperature stress

Hydroxypropyl cellulose can also contribute to release control because it hydrates and modifies the structure of the matrix. That makes it more than a purely processing-oriented excipient in some formulations.

What commercial opportunities exist for APLENZIN excipients?

The largest opportunities are formulation development, generic substitution, contract manufacturing, and product differentiation. The market is narrower than the market for generic bupropion hydrochloride because APLENZIN uses a different salt and a specific extended-release product design.

Generic APLENZIN development

A generic applicant would likely seek approval through an abbreviated new drug application if the proposed product can meet the applicable requirements for pharmaceutical equivalence, bioequivalence, manufacturing quality, and labeling. The main technical risk is not simply reproducing the inactive ingredient list. It is reproducing the release profile and systemic exposure of the reference product.

A generic strategy could use:

1. The same listed excipients at different levels.
2. A functionally equivalent polymer-lipid matrix.
3. A different matrix technology supported by comparative dissolution and bioequivalence data.
4. A multiparticulate or coated-particle design, if permitted by the product-specific regulatory framework.

A formulation that matches the excipient list but fails to match release behavior has limited commercial value.

Reformulated or differentiated products

A 505(b)(2) strategy could target features not provided by the existing tablet, including:

• Smaller tablets at equivalent dose
• Improved swallowability
• Alternative dosing formats
• Modified release profiles
• Lower excipient burden
• Reduced sensitivity to food or gastrointestinal conditions
• More robust stability in hot and humid markets

Any reformulation that changes the release mechanism must address dose dumping, seizure-related safety concerns, pharmacokinetic comparability, and labeling. Bupropion’s known seizure risk makes aggressive release acceleration commercially unattractive.

Excipient supplier opportunities

Excipient suppliers can compete through controlled grades and technical support rather than through commodity pricing alone. The most relevant products are:

• High-purity ethylcellulose grades
• Controlled-viscosity hydroxypropyl cellulose
• Direct-compression glyceryl behenate
• Low-moisture povidone
• High-flow colloidal silicon dioxide
• Low-reactivity magnesium stearate

Supplier differentiation can include dissolution modeling, scale-up support, compaction data, and regulatory documentation. For a controlled-release product, a supplier’s ability to maintain lot-to-lot particle-size distribution and viscosity is commercially important.

What formulations are protected by APLENZIN-related intellectual property?

The commercial protection for APLENZIN is likely to depend on several patent categories rather than on the mere use of a common excipient:

Potential protection category	Relevance to APLENZIN
Bupropion hydrobromide composition	Protects the selected active salt or pharmaceutical composition
Extended-release matrix	Covers polymer, lipid, binder, or release-control combinations
Dissolution profile	May define release windows or pharmacokinetic behavior
Dose strengths	May cover 174 mg, 348 mg, or 522 mg compositions
Method of treatment	May cover treatment of depression or seasonal affective disorder
Manufacturing process	May cover granulation, compression, coating, or scale-up parameters
Product-by-process features	May protect a product defined partly by manufacturing conditions

Common excipients such as ethylcellulose, povidone, and magnesium stearate are unlikely to provide meaningful protection by themselves. Patent strength would depend on the combination, concentration ranges, release performance, and non-obvious technical effect.

A formulation patent is stronger when it claims a narrow, reproducible combination that produces a distinctive release profile. It is weaker when it claims broad use of known excipients without a demonstrated technical advantage.

When does APLENZIN lose exclusivity?

FDA regulatory exclusivity and patent exclusivity are separate.

Exclusivity category	APLENZIN relevance
New chemical entity exclusivity	Unlikely to remain the principal barrier for a product approved in 2009
Orphan-drug exclusivity	Not the primary basis for APLENZIN’s depression indications
Pediatric exclusivity	Could add six months if granted, but must be confirmed in FDA records
Orange Book patents	May affect ANDA timing and Paragraph IV litigation
Formulation or method patents	May delay or limit generic entry if valid and enforceable
Regulatory data exclusivity	Generally less important than patent and bioequivalence barriers for an older small-molecule product

APLENZIN was approved by FDA in 2009 under NDA 021515.[4] A current exclusivity analysis must distinguish expired regulatory periods from any unexpired Orange Book-listed patents. The FDA Orange Book, rather than the prescribing information, is the controlling source for current patent listings, expiration dates, and generic approval status.[5]

What is the Orange Book status of APLENZIN?

APLENZIN is an FDA-approved small-molecule prescription product. It is not a biologic, so biosimilar law does not apply. Competitive entry would occur through an ANDA or, for a materially different product, potentially through a 505(b)(2) application.

The commercial questions for an ANDA applicant are:

• Whether APLENZIN remains the designated reference listed drug.
• Whether APLENZIN-specific patents are listed in the Orange Book.
• Whether any listed patent has an unexpired term.
• Whether a Paragraph IV certification has been filed.
• Whether the NDA holder has sued within the statutory window.
• Whether litigation resulted in a 30-month stay.
• Whether a settlement restricts the first commercial launch date.

The FDA label does not provide a complete patent schedule. Patent numbers, expiration dates, and Paragraph IV events must be evaluated from the current Orange Book and FDA litigation records.[1,5]

Are there Paragraph IV challenges or generic launch risks?

A Paragraph IV challenge would assert that a listed patent is invalid, unenforceable, or not infringed. For APLENZIN, the most likely technical challenge areas would involve:

• Whether the claims cover the proposed salt or only a narrower composition.
• Whether the generic uses a different polymer-lipid matrix.
• Whether a dissolution-profile claim is infringed.
• Whether method-of-use claims can block a product labeled for all approved indications.
• Whether manufacturing-process claims reach the generic’s process.

The main generic launch scenarios are:

Scenario	Commercial outcome
No approved generic	Brand retains broad pricing control, subject to payer pressure
First approved generic without litigation delay	Rapid price erosion and pharmacy substitution risk
Tentative approval blocked by litigation	Delayed launch until settlement, judgment, or patent expiry
Authorized generic launch	Brand holder can moderate erosion and capture lower-price demand
505(b)(2) reformulation	Differentiated product may avoid direct tablet substitution

Because APLENZIN is an extended-release bupropion product, a generic applicant faces greater development risk than an immediate-release tablet applicant. Bioequivalence failure, food-effect differences, or dissolution mismatch can delay approval.

How strong is the APLENZIN patent estate?

The likely strength is mixed.

The active ingredient is a mature small molecule, and the broad concept of extended-release bupropion is not new. Those factors reduce the strength of broad composition claims. Narrow formulation claims can still have value if they cover a specific bupropion hydrobromide matrix, a defined dissolution profile, or a manufacturing process that competitors cannot easily design around.

Patent feature	Relative strength
Broad bupropion composition claim	Low to moderate for a mature active
Specific bupropion hydrobromide formulation	Moderate
Defined extended-release dissolution profile	Moderate, dependent on claim construction
Narrow manufacturing process	Moderate to high if difficult to design around
Broad use of standard excipients	Low
Method-of-use claim for depression	Moderate to low against a fully labeled generic, depending on claim scope

The practical barrier may be formulation development rather than patent scope. A competitor may avoid direct infringement but still need extensive development work to match the reference product.

What litigation and settlement issues affect APLENZIN?

Relevant litigation would typically involve a patent-holder suit following a Paragraph IV notice. The principal legal issues would be infringement of formulation claims, validity of polymer or salt claims, and the timing of generic launch.

A settlement could provide:

• A fixed future launch date.
• An authorized-generic arrangement.
• A license to manufacture or distribute.
• Restrictions on the generic’s label.
• A waiver of some claims in exchange for commercial terms.

No litigation or settlement conclusion should be inferred from the existence of an Orange Book listing alone. Listing creates a potential pathway for litigation; it does not establish infringement or patent validity.

How does APLENZIN compare with Wellbutrin XL?

Attribute	APLENZIN	Wellbutrin XL
Active salt	Bupropion hydrobromide	Bupropion hydrochloride
Dosage form	Extended-release tablet	Extended-release tablet
Daily dosing	Once daily	Once daily
Key commercial distinction	Salt-specific product and formulation	Larger established bupropion XL franchise
Generic substitution	Requires product-specific approval	Separate from APLENZIN approval
Biosimilar risk	None	None
Main technical barrier	Salt and release-profile matching	Release-profile matching

A generic bupropion hydrochloride extended-release product does not automatically substitute for APLENZIN. The products have different active salts and reference-product pathways.

What revenue exposure and market opportunities exist?

Revenue exposure depends on the extent of branded sales, payer coverage, generic availability, and physician willingness to prescribe a salt-specific product. The most material downside event would be an approved, therapeutically substitutable generic that reaches retail pharmacies without a meaningful litigation delay.

Commercial opportunities include:

• Authorized-generic distribution.
• Licensing the formulation platform.
• Contract development and manufacturing for bupropion ER products.
• Excipient supply agreements.
• Reformulated tablets with improved swallowability.
• International registration using the same matrix technology.
• Lifecycle products using alternative strengths or delivery formats.

Geographic expansion is constrained by national requirements for bioequivalence, modified-release testing, stability, and local patent rights. A formulation cleared in the United States may require additional comparative dissolution and pharmacokinetic work in Europe and other regulated markets.

Key Takeaways

• APLENZIN is a bupropion hydrobromide extended-release tablet approved for major depressive disorder and prevention of seasonal major depressive episodes.
• Its excipient platform uses ethylcellulose and glyceryl behenate for release control, with povidone and hydroxypropyl cellulose supporting processing and matrix performance.
• The strongest commercial opportunity is a product that matches the reference release profile while using a scalable, cost-efficient matrix.
• Bupropion hydrochloride generics are not automatically substitutes for APLENZIN because the active salts differ.
• APLENZIN has no biosimilar exposure. Competitive entry would occur through an ANDA or a 505(b)(2) pathway.
• Patent value is likely concentrated in salt-specific compositions, extended-release matrices, dissolution profiles, and manufacturing processes.
• Current patent expiration, Paragraph IV, litigation, and settlement conclusions require Orange Book and FDA records, not the product label alone.

FAQs

Can ethylcellulose alone reproduce the APLENZIN release profile?

No. Release performance depends on polymer grade, concentration, particle size, matrix porosity, glyceryl behenate, binders, compression conditions, and dissolution testing.

Is bupropion hydrobromide interchangeable with bupropion hydrochloride?

No. The salts have different molecular weights and are approved under separate product-specific regulatory pathways.

Can APLENZIN be reformulated as a capsule?

Potentially, but a capsule reformulation would need to demonstrate comparable release, exposure, stability, labeling, and safety. It may require a 505(b)(2) pathway rather than ordinary generic substitution.

Which excipient creates the greatest development risk?

Ethylcellulose is likely the largest release-control variable, but the interaction between ethylcellulose and glyceryl behenate may determine the final dissolution profile.

Does APLENZIN have biosimilar competition?

No. APLENZIN is a small-molecule drug. Its competitors would be generic or reformulated bupropion products, not biosimilars.

References

1. U.S. Food and Drug Administration. (2024). APLENZIN (bupropion hydrobromide) extended-release tablets prescribing information.
2. Rowe, R. C., Sheskey, P. J., & Quinn, M. E. (Eds.). (2009). Handbook of pharmaceutical excipients (6th ed.). Pharmaceutical Press.
3. U.S. Food and Drug Administration. (2017). Guidance for industry: Extended release solid oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations.
4. U.S. Food and Drug Administration. (2009). Drugs@FDA: APLENZIN NDA 021515.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed.: Orange Book.